Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression

BJU International, Supplement

Volumn 95, Issue 4, 2005, Pages 6-11

  Trachtenberg, John ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

1 adrenoceptor antagonists; Acute urinary retention; BPH; Drug therapy; LUTS; Risk factors; Treatment failure

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

DISEASE COURSE; HIGH RISK PATIENT; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RESIDUAL URINE; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; URINARY TRACT DISEASE; URINE FLOW RATE; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT FAILURE; URINARY RETENTION;

EID: 18944366611     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05488.x     Document Type: Review

References (38)

1. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 2001; 39: 390-9
2. Palacio A, Hernández C, Marqués A, Prats J, Espinosa FJ. Long term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report. Arch Esp Urol 2004; 57: 451-60
3. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98
4. Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119-26
5. Roehrborn CG, McConnell JD, Lieber M et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473-80
6. Jiménez-Cruz F. Identifying patients with lower urinary tract symptoms/ benign prostatic hyperplasia (LUTS/BPH) at risk for progression. Eur Urol Suppl 2003; 2: 6-12
7. Artibani W. Integrating the patient risk profile in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Eur Urol Suppl 2004; 3: 1-6
8. Speakman MJ. Lower urinary tract symptoms suggestive of benign prostatic obstruction: what is the available evidence for rational management? Eur Urol 2001; 39 (Suppl. 3): 6-12
9. Stoevelaar HJ, McDonnell J, Bosch JL et al. Lower urinary tract symptoms suggestive of benign prostatic obstruction: how can clinical expertise contribute to rational management? Eur Urol 2001; 39 (Suppl 3): 13-9
10. Lowe F, Batista J, Chartier-Kastler E et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia; a systematic analysis of expert opinion. Eur Urol Suppl 2004; 3: 39 (Abstract 146)
11. Djavan B, Nickel JC, de la Rosette J, Abrams P. The urologist view of BPH progression: results of an international survey. Eur Urol 2002; 41: 490-6
12. Jacobsen SJ, Jacobsen DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7
13. Marberger MJ, Andersen JT, Nickel JC et al. Prostate Volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 2000; 38: 563-8
14. McConnell JD, Roehrborn CG, Slawin KM et al. Baseline measures predict the risk of benign prostatic hyperplasia clinical progression in placebo-treated patients. J Urol 2003; 169: 332 (Abstract 1287)
15. Speakman MJ. Integrating patient risk profiles in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in clinical practice. Eur Urol Suppl 2004; 3: 18-22
16. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Lieber MM. Serum PSA levels predict acute urinary retention in 40-79 year old community men in Olmsted County, MN. J Urol 1999; 161: 288 (Abstract. 1118)
17. Jacobsen SJ, Jacobsen DJ, Girman CJ, Roberts RO, Rhodes T, Lieber MM. Acute urinary retention in community-dwelling men: 9-year followup of the olmsted county study of urinary symptoms and health status among men. Eur Urol Suppl 2003; 2: 26 (Abstract 95)
18. Jacobsen SJ, Jacobsen DJ, Girman CJ, Roberts RO, Rhodes T, Lieber MM. Acute urinary retention in community-dwelling men: 9-year followup of the olmsted county study of urinary symptoms and health status among men. J Urol 2003; 169: 365 (Abstract 1364)
19. Lieber MM, Jacobsen DJ, Girman CJ, Roberts RO, Rhodes T, Jacobsen SJ. Incidence of lower urinary tract symptom progression in community-dwelling men. 9-year followup of the Olmsted County study of urinary symptoms and health status among men. J Urol 2003; 169: 366-7 (Abstract. 1369)
20. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 1999; 162: 376-82
21. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-63
22. Roehrborn CG, McConnell JD, Saltzman B et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 2002; 42: 1-6
23. McNicholas T. LUTS, the case is altered. Eur Urol Suppl 2002; 1: 28-35
24. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530-47
25. Chatelain C, Denis L, Foo JK et al. Evaluation and treatment of lower urinary tract symptoms (LUTS) in older men. Benign Prostatic Hyperplasia. 5th International Consultation on Benign Prostatic Hyperplasia (BPH), June 25-28, 2000 Paris. Plymouth: Plymbridge Distributors Ltd 2001: 519-34
26. Vaughan ED Jr. Medical management of benign prostatic hyperplasia - are two drugs better than one? N Engl J Med 2003; 349: 2449-51
27. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
28. Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335: 533-9
29. Debruyne FM, Jardin A, Colloi D et al. Sustained-release alfuzosin, finsteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998; 34: 169-75
30. Rigatti P, Brausi M, Scarpa RM et al. A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2003; 6: 315-23
31. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) Urology 2005; in press
32. Kaplan SA, Roehrborn CG, McConnell JD et al. Baseline symptoms, uroflow, and post-void residual urine as predictors of BPH clinical progression in medically treated arms of the MTOPS trial. J Urol 2003; 169: 332 (Abstract 1289)
33. Speakman M, Berges R, Desgrandchamps F et al. Integrating risk profiles in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia. A systematic analysis of expert opinion. Eur Urol Suppl 2004; 3: 61 (Abstract 232)
34. Logie JW, Clifford GM, Farmer RD, Meesen BP. Lower urinary tract symptoms suggestive of benign prostatic obstruction - Triumph: the role of general practice databases. Eur Urol 2001; 39 (Suppl. 3): 42-7
35. de la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA. Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms. J Urol 2002; 167: 1734-9
36. Barendrecht MM, Koopmans RP, de La Rosette JJ, Michel MC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 2005; 95 (Suppl 4): 19-28
37. 1-adrenoceptor antagonists. BJU Int 2005; 95 (Suppl 4): 29-36
38. Lowe FC. Patient risk profiles for progression of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Eur Urol Suppl 2004; 3: 7-11